Clinical Trials in New York

Showing 12281-12300 of 22,668 trials

A Novel Approach to Infantile Spasms

NCT03347526

This study proposes to assess the efficacy of Cosyntropin Injectable Suspension, 1 mg/mL compared to vigabatrin. Additionally, this study proposes to determine efficacy of combination therapy of Cosyntropin Injectable Suspension, 1 mg/mL and vigabatrin to monotherapy Cosyntropin Injectable Suspension, 1mg/mL in children with new onset infantile spasms (IS).

Infantile Spasm

University of Colorado, Denver394 participantsStarted Apr 2018

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +11 more locations

COMPLETEDPhase 1< 1 mile

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

NCT01662804

The purpose of this study is to find out if "humanized 3F8" (Hu3F8) when combined with interleukin-2 (rIL2) is safe for treating neuroblastoma and other cancers. A phase 1 study means the investigators are trying to find out what side effects happen when higher and higher doses of a drug are used. The investigators want to find out what effects, good and/or bad, Hu3F8 combined with rIL2 has on cancer. The amount of Hu3F8 that patients gets will depend on when they start treatment on this study. The amount of rIL2 will be the same for all patients. The investigators also want to find out more about how Hu3F8 works and how effective it is in attacking the disease when combined with rIL2.

Neuroblastoma

Memorial Sloan Kettering Cancer Center14 participantsStarted Aug 2012

New York, New York, United States

A Novel Approach to Infantile Spasms

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Find Trials by Condition in New York

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Cardiopulmonary Rehabilitation in COVID-19 Longhaulers

BAX 855 Pediatric Study

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

Treatment Protocol of Replagal for Patients With Fabry Disease

Response to Anti-hypertensives in Pregnant and Postpartum Patients

Registry of Sustained Immunity to COVID-19 Among ESKD Patients

DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

Smoking Cessation Treatment for Methadone Maintenance Patients

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

Early Prophylaxis Immunologic Challenge (EPIC) Study

Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy (PEP ASV)

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

BAX 855 PK-guided Dosing